Abstract: The invention is directed to liquid pharmaceutical compositions comprising at least 15mg/ml of sildenafil citrate, their use in treating erectile dysfunction and their methods of manufacture.

Abstract: A method comprising: administering an effective amount of a topical dipyridamole to a subject in need thereof due to an eye disorder selected from the group consisting of keratitis, corneal abrasion and corneal ulcer.

Abstract: A method comprising: administering an effective amount of a topical dipyridamole to a subject in need thereof due to an eye disorder selected from the group consisting of keratitis, corneal abrasion and corneal ulcer.

Abstract: A method comprising: administering an effective amount of a topical dipyridamole to a subject in need thereof due to a disorder selected from the group consisting of keratitis, corneal abrasion and corneal ulcer.

Abstract: A method comprising: (a) identifying a subject in need of treatment for cataract and/or nevus and/or tumor lesion; and (b) topically administering to the eye an amount of dipyridamole which is physiologically effective in treatment of cataract and/or nevus and/or melanoma.

Abstract: A method comprising: administering an effective amount of a topical dipyridamole to a subject in need thereof due to a disorder selected from the group consisting of keratitis, corneal abrasion and corneal ulcer.

Abstract: A method comprising administering an effective amount of a topical dipyridamole to a subject in need thereof due to conjunctivitis.

Abstract: A pharmaceutical composition comprising a liquid carrier comprising water and at least 35% of ethanol and sildenafil citrate dissolved in said liquid carrier at a concentration of at least 7 mg/ml.

Abstract: A composition comprising about 10 mg or less of dipyridamole formulated for oral administration and a physiologically acceptable carrier.

Abstract: A pharmaceutical composition comprising a liquid carrier comprising water and at least 35% of ethanol and sildenafil citrate dissolved in said liquid carrier at a concentration of at least 7 mg/ml.

Abstract: A method comprising: (a) identifying a subject in need of treatment for cataract and/or nevus and/or tumor lesion; and (b) topically administering to the eye an amount of dipyridamole which is physiologically effective in treatment of cataract and/or nevus and/or melanoma.

Abstract: A pharmaceutical composition comprising: (a) a liquid carrier comprising water and at least 20% of at least one alcohol; and (b) sildenafil citrate dissolved in said liquid carrier at a concentration of at least 7 mg/ml.

Abstract: A method comprising administering an effective amount of a topical dipyridamole to a subject in need thereof due to conjunctivitis.

Abstract: A method comprising the step of: administering an effective amount of a topical dipyridamole to a subject in need thereof due to an eye disorder selected from the group consisting of pterygium and pinguecula.

Abstract: A treatment method including: (a) identifying a subject in need of treatment for androgenic alopecia (AGA), and (b) orally administering a physiologically effective amount of cepharanthine (CEP) to the subject according to a dosage regimen.

Abstract: A method comprising the step of: administering an effective amount of a topical dipyridamole to a subject in need thereof due to an eye disorder selected from the group consisting of pterygium and pinguecula.

Abstract: A pharmaceutical composition comprising: (a) a liquid carrier comprising water and at least 20% of at least one alcohol; and (b) sildenafil citrate dissolved in said liquid carrier at a concentration of at least 7 mg/ml.

Abstract: A treatment method including: (a) identifying a subject in need of treatment for androgenic alopecia (AGA), and (b) orally administering a physiologically effective amount of cepharanthine (CEP) to the subject according to a dosage regimen.

Abstract: The present invention discloses methods for treating eye disorders. The methods include the step of administering an effective amount of a topically-administered dipyridamole. Preferably, the topically-administered dipyridamole is formulated as a solution. Preferably, the topically-administered dipyridamole is at least one agent selected from the group consisting of: dipyridamole, and a pharmaceutically-acceptable salt thereof. Preferably, the effective amount corresponds to a concentration of at least about 10?5 molarity. Preferably, the effective amount is based on a treatment administration of at least once every other day.

Abstract: An off-label medical use portal, including a centralized database encoded on a computer readable-medium, a collecting mechanism for collecting information regarding off-label medical use, a peer-review mechanism for vetting collected information, and an access mechanism for providing access to unvetted and vetted information in electronic communication with the centralized database. A method of using the off-label medical use portal by submitting publications about off-label medical use to the portal, peer-reviewing the publications, and providing access to non-peer-reviewed and peer-reviewed information and publications to interested individuals.